Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Cutaneous Squamous Cell Carcinoma
DRUG: Ivonescimab
Safety and adverse events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year.
Primary Objective - To determine the ORR of ivonescimab in participants with cSCC

Secondary Objectives

* To evaluate other indicators of the antitumor efficacy of ivonescimab in participants with cSCC.
* To evaluate the safety and tolerability of ivonescimab in participants with cSCC

Exploratory Objective

- To evaluate potential predictors of response and resistance to ivonescimab in participants with cSCC.